From lab to market: pHyph is now approved for launch in the EU

Bacterial vaginosis (BV), a common vaginal infection caused by an imbalance in the natural bacteria of the vagina, affects up to one in four women annually, often causing significant stress. Conventional antibiotic treatments typically prescribed by doctors can disrupt the natural vaginal microbiome, leading to high rates of recurrence and secondary yeast infections. Gedea Biotech’s novel antibiotic-free treatment for bacterial vaginosis (BV), called pHyph, is now CE-marked and approved for sale in Europe. 



Gedea Biotech was founded by four researchers from Lund University and Skåne University Hospital: Ulf Ellervik, Helena Strevens, Sophie Manner, and the late Olov Sterner.